<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053192</url>
  </required_header>
  <id_info>
    <org_study_id>19-003 BAV</org_study_id>
    <nct_id>NCT04053192</nct_id>
  </id_info>
  <brief_title>Evaluation of BAV in Different Hemodynamic Entities of Severe AS</brief_title>
  <acronym>BAV</acronym>
  <official_title>Contemporary Use of Percutaneous Balloon Aortic Valvuloplasty and Evaluation of Its Success in Different Hemodynamic Entities of Severe Aortic Valve Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this retrospective, observational study is to compare the profit of BAV and
      TAVI in different subtypes of serve aortic stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Balloon Aortic Valvuloplasty (BAV) is a catheter-based intervention, which can be used
      for dilatation of serve aortic stenosis. With this minimally invasive intervention an
      increase of the aortic valve area (AVA) and cardiac ejection fraction (EF), decrease of
      transvalvular gradients and ultimately a symptom relief should be achieved. The required
      effect is temporary and a definitive treatment should be aspired in suitable patients.
      Therefor Transcatheter Aortic Valve Replacement (TAVR) is available.

      Following the guidelines of the European Society of Cardiology for the management of valvular
      heart disease from 2017, the aortic stenosis can be divided into different subtypes by using
      haemodynamic parameters: High-gradient AS (HG-AS), Low-Flow-Low-Gradient AS (LFLG-AS) and
      paradoxical Low-Flow-Low-Gradient (pLFLG-AS). Patients with LFLG-AS are suspected to have a
      poorer prognosis when treated curative as well as when treated palliative medicamentous,
      because these patients show coronary and myocardial restrictions more frequently in addition
      to the valvular disease.

      The aim of the study is to compare safety and effectiveness of balloon aortic valvuloplasty
      as a bridging therapy and transcatheter aortic valve replacement as a definitive treatment in
      HG-AS, LFLG-AS and pLFLG-AS patients to verify whether the subtypes of aortic stenosis profit
      equally from these interventions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>1-Year post BAV</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Procedure Hemodynamic Changes</measure>
    <time_frame>24 - 72 h after procedure</time_frame>
    <description>dPmean, dPmax, AVA, Vmax, EF; Evaluation by using the first echocardiographic parameters after BAV / TAVR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with myocardial infarction</measure>
    <time_frame>30 days after intervention</time_frame>
    <description>Evaluation by using the VARC-2 definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with stroke</measure>
    <time_frame>30 days after intervention</time_frame>
    <description>Evaluation by using the VARC-2 definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with bleeding complications</measure>
    <time_frame>30 days after intervention</time_frame>
    <description>Evaluation by using the VARC-2 definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with acute kidney injury</measure>
    <time_frame>30 days after intervention</time_frame>
    <description>Evaluation by using the VARC-2 definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with vascular complications</measure>
    <time_frame>30 days after intervention</time_frame>
    <description>Evaluation by using the VARC-2 definition</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">166</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>High-Gradient Aortic Stenosis (HG-AS)</arm_group_label>
    <description>(Pmean &gt;40mmHg, AVA &lt;1cm^2, Vmax &gt;4m/s)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Flow-Low-Gradient Aortic Stenosis (LF-LG)</arm_group_label>
    <description>(Pmean &lt;40mmHg, AVA &lt;1cm^2, Vmax &lt;4m/s, EF &lt;50%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paradoxe Low-Flow Low Gradient Aortic Stenosis (pLF-LG AS)</arm_group_label>
    <description>Pmean &lt;40mmHg, AVA &lt;1cm^2, Vmax &lt; 4m/s, EF &gt;50%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BAV</intervention_name>
    <description>BAV</description>
    <arm_group_label>High-Gradient Aortic Stenosis (HG-AS)</arm_group_label>
    <arm_group_label>Low-Flow-Low-Gradient Aortic Stenosis (LF-LG)</arm_group_label>
    <arm_group_label>Paradoxe Low-Flow Low Gradient Aortic Stenosis (pLF-LG AS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BAV + TAVR</intervention_name>
    <description>BAV + TAVR</description>
    <arm_group_label>High-Gradient Aortic Stenosis (HG-AS)</arm_group_label>
    <arm_group_label>Low-Flow-Low-Gradient Aortic Stenosis (LF-LG)</arm_group_label>
    <arm_group_label>Paradoxe Low-Flow Low Gradient Aortic Stenosis (pLF-LG AS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SAVR</intervention_name>
    <description>Surgical aortic valve replacement (SAVR)</description>
    <arm_group_label>High-Gradient Aortic Stenosis (HG-AS)</arm_group_label>
    <arm_group_label>Low-Flow-Low-Gradient Aortic Stenosis (LF-LG)</arm_group_label>
    <arm_group_label>Paradoxe Low-Flow Low Gradient Aortic Stenosis (pLF-LG AS)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in the heart failure program of the University of Duesseldorf
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Severe Aortic Stenosos who underwent BAV

        Exclusion Criteria:

          -  insufficient echocardiographic parameters before BAV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>97 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Zeus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Div. of Heinrich-Heine-University, Div. of Cardiology, Pulmonary Disease and Vascular Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonary Disease and Vascular Medicine</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik f√ºr Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Principle Investigator PD Dr. Zeus</investigator_title>
  </responsible_party>
  <keyword>Balloon Aortic Valvuloplasty</keyword>
  <keyword>Severe Aortic Valve Stenosis</keyword>
  <keyword>Surgical aortic valve replacement (SAVR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

